1.. INTRODUCTION
================

Metastatic renal cell carcinoma ([rcc]{.smallcaps}) is estimated to have caused 13,010 deaths in the United States in 2008 [@b1-co16-s1-s16]. Previously, immunotherapy agents such as interleukin-2 and interferon alpha ([ifn]{.smallcaps}α) were the only treatments available, and they demonstrated low response rates of approximately 15% [@b2-co16-s1-s16]--[@b7-co16-s1-s16]. The biology underlying [rcc]{.smallcaps} has been elucidated, and agents targeting relevant biologic pathways have been investigated [@b8-co16-s1-s16]. This targeting developed chiefly from an understanding of von Hippel--Lindau ([vhl]{.smallcaps}) syndrome, which is an inherited, autosomal dominant genetic disorder that commonly manifests in the development of clear-cell [rcc]{.smallcaps} in affected patients. The present review details the current evidence behind traditional approaches, including cytoreductive nephrectomy, metastasectomy, and immunotherapy, and then provides an overview of the contemporary targeted therapies and related ongoing clinical trials.

2.. SURGERY IN PATIENTS WITH METASTATIC DISEASE
===============================================

Radical nephrectomy has been indicated even for [rcc]{.smallcaps} patients with metastatic disease. Two phase [iii]{.smallcaps} studies randomized patients to [ifn]{.smallcaps}α with or without cytoreductive radical nephrectomy. In a combined analysis of these trials, median survival was 7.8 months in patients treated with [ifn]{.smallcaps}α alone as compared with 13.6 months for patients who received [ifn]{.smallcaps}α plus cytoreductive nephrectomy [@b9-co16-s1-s16]--[@b11-co16-s1-s16]. A greater survival advantage was observed in patients with better performance status. This cytoreductive paradigm remains predominant in the era of targeted therapy because clinical trials demonstrating the benefits of targeted therapy have largely been observed in the context of prior nephrectomy [@b12-co16-s1-s16]--[@b16-co16-s1-s16]. It remains to be seen whether the observation of shrinkage in the primary tumour with targeted agents may alter this paradigm in future. A randomized trial to clarify the value of cytoreductive nephrectomy is currently in development (A. Ravaud, personal communication).

Although cytoreductive nephrectomy appears to benefit many patients with metastatic [rcc]{.smallcaps}, it is not curative, and it should not be performed indiscriminately. Patients who are most likely to benefit from cytoreduction include those with

-   substantial tumour burden (for example, in excess of 75%) in the involved kidney,

-   good performance status, and

-   no central nervous system or liver metastases (with rare exceptions) [@b17-co16-s1-s16].

Other considerations pertain to surgical resectability, particularly the potential for morbidity if proximity to vital structures, encasement of the renal hilum, or other complicating factors are present. Because of lower operative morbidity and mortality, laparoscopic nephrectomy is emerging as the standard surgical procedure whenever technically feasible.

Patients with disseminated [rcc]{.smallcaps} and a solitary metastasis may be considered for metastasectomy, although they represent a small fraction of cases. Favourable prognostic factors include a long interval between initial diagnosis and development of the metastasis, which reflects an indolent course and reinforces the likelihood that the metastasis is truly solitary. Additionally, complete resection of the metastatic disease should be possible (for example, solitary pulmonary nodule), so that the patient can be said to have no evidence of disease [@b18-co16-s1-s16]. Patients with favourable-to-intermediate prognostic features may achieve a 5-year survival of 38%--71% with metastasectomy, and thus surgical resection of metastases should be considered in appropriately selected [rcc]{.smallcaps} patients [@b19-co16-s1-s16].

3.. IMMUNOTHERAPY
=================

Early trials using chemotherapy did not produce a significant benefit [@b20-co16-s1-s16],[@b21-co16-s1-s16], and so, in an attempt to harness the innate immune response of [rcc]{.smallcaps} tumours, immunotherapy has long been the standard of care for the treatment of metastatic [rcc]{.smallcaps}. Treatment with [ifn]{.smallcaps}α produced response rates of up to 15%, with modest to no prolongation of overall survival ([os]{.smallcaps}), in comparisons with inactive controls [@b5-co16-s1-s16],[@b6-co16-s1-s16]. A pooled analysis investigating the use of high-dose interleukin-2 ([il]{.smallcaps}-2) revealed an overall response rate ([orr]{.smallcaps}) of 14%, with 5% complete responses [@b22-co16-s1-s16]. Most patients achieving a complete response had durable disease remission. Notably, significant side effects were observed, including capillary leak syndrome, which necessitated intensive blood pressure monitoring and the occasional requirement for vasopressors.

Phase [iii]{.smallcaps} trials of high-dose [il]{.smallcaps}-2 failed to demonstrate significant benefit in comparisons with low-dose cytokine regimens [@b2-co16-s1-s16],[@b3-co16-s1-s16]. High-dose [il]{.smallcaps}-2 is noteworthy for a small but real percentage of durable complete remissions; however, this treatment strategy is able to be applied only in a small, highly selected fraction of [rcc]{.smallcaps} cases. Even the occasional patient with very extensive disease, including involvement of lung, bone, or liver, may sustain a remission measured in years. Attempts to precisely characterize and identify this group of responders have been uniformly unsuccessful, however, which makes the use of this treatment strategy very challenging.

4.. BIOLOGIC BASIS OF TARGETED THERAPY: VHL
===========================================

The recognition of hereditary renal neoplasms catalyzed the discovery of the genetic basis of [rcc]{.smallcaps}. Clinically, the [vhl]{.smallcaps} syndrome, a constellation of cysts and tumours in the central nervous system and abdominal viscera [@b8-co16-s1-s16], is inherited in an autosomal dominant fashion. The central nervous system lesions include retinal hemangioblastomas, endolymphatic sac tumours, and craniospinal hemangioblastomas. The visceral lesions in these patients include clear-cell [rcc]{.smallcaps}s, pheochromocytomas, neuroendocrine pancreatic tumours, epididymal cystadenomas, and broad ligament cystadenomas.

Patients with [vhl]{.smallcaps} syndrome have an aberrant *VHL* allele on chromosome 3p25, which predisposes them to disease if the second allele is mutated. This configuration is a prime example of the classical "two-hit hypothesis" for genes with a tumour-suppressor function. The [vhl]{.smallcaps} 213-amino-acid protein polyubiquinates hypoxia-inducible factor ([hif]{.smallcaps}), which marks that factor for destruction by the cellular proteasome. Normally, low oxygen conditions allow [hif]{.smallcaps}α to accumulate and bind to [hif]{.smallcaps}β, thereby creating a complex that transcriptionally activates genes. In patients with aberrant *VHL*, [hif]{.smallcaps}α is left to freely accumulate without degradation, even under normal oxygen conditions. Thus, the transcription of genes related to glucose metabolism, apoptosis, angiogenesis, and endothelial stabilization are abnormally promoted. This disordered response to hypoxia activates more than 100 [hif]{.smallcaps}-responsive genes that include growth factors and their receptors such as vascular endothelial growth factor ([vegf]{.smallcaps}), platelet-derived growth factor ([pdgf]{.smallcaps}), and transforming growth factors alpha and beta [@b23-co16-s1-s16].

Nonhereditary, sporadic clear-cell [rcc]{.smallcaps} also exhibits *VHL* aberrations [@b23-co16-s1-s16]. A single *VHL* allele deletion occurs in approximately 78.4%--98% of sporadic tumours [@b24-co16-s1-s16]--[@b29-co16-s1-s16]. For the remaining allele, *VHL* gene mutations are seen in 34%--57%, and gene inactivation via hypermethylation of CpG--rich [dna]{.smallcaps} islands occurs in about 5%--20.4% of clear-cell [rcc]{.smallcaps} [@b24-co16-s1-s16],[@b27-co16-s1-s16],[@b28-co16-s1-s16],[@b30-co16-s1-s16],[@b31-co16-s1-s16]. Thus, it is clear that, in hereditary and sporadic cases of clear-cell [rcc]{.smallcaps} alike, *VHL* abnormalities are a key in the pathogenesis.

5.. TARGETED THERAPY
====================

With an understanding of the biology behind metastatic [rcc]{.smallcaps}, new drugs have been developed to target downstream effectors of [vhl]{.smallcaps} and [hif]{.smallcaps} ([Table [i]{.smallcaps}](#t1-co16-s1-s16){ref-type="table"}), including [vegf]{.smallcaps}, [pdgf]{.smallcaps}, and mammalian target of rapamycin (m[tor]{.smallcaps}). Drugs such as sunitinib and sorafenib target the [vegf]{.smallcaps} receptor ([vegfr]{.smallcaps}), and drugs such as bevacizumab target the [vegf]{.smallcaps} ligand. Other drugs such as temsirolimus and everolimus target downstream effectors of [vegf]{.smallcaps}, including m[tor]{.smallcaps} kinase. All of these drugs have demonstrated efficacy in the treatment of metastatic [rcc]{.smallcaps} and have been incorporated into the current treatment algorithm ([Table [ii]{.smallcaps}](#t2-co16-s1-s16){ref-type="table"}).

5.1. VEGFR Tyrosine Kinase Inhibitors
-------------------------------------

Receptor tyrosine kinases ([rtk]{.smallcaps}s) play an integral role in the signalling cascade of [vegf]{.smallcaps} and [pdgf]{.smallcaps} [@b34-co16-s1-s16]. An extracellular domain of the [rtk]{.smallcaps}s binds to the respective ligand, and an intracellular domain holds the tyrosine kinase responsible for downstream signalling. Upon ligand binding, the [rtk]{.smallcaps}s dimerize or multimerize to induce a conformational change that permits binding of adenosine triphosphate, resulting in autophosphorylation and transphosphorylation. These tyrosine domains are then able to phosphorylate and activate various proteins in the downstream signal transduction cascade.

### 5.1.1. Sunitinib

Sunitinib is an oral multikinase inhibitor that blocks [vegfr]{.smallcaps}s 1, 2, and 3, [pdgf]{.smallcaps} receptor beta and related [rtk]{.smallcaps}s [@b35-co16-s1-s16]. Initial phase [ii]{.smallcaps} trials of sunitinib in metastatic [rcc]{.smallcaps} (in 169 patients who had failed prior cytokine-based therapy) demonstrated an investigator-assessed objective response rate of 45%, a median duration of response of 11.9 months, and a median progression-free survival ([pfs]{.smallcaps}) of 8.4 months [@b36-co16-s1-s16]--[@b38-co16-s1-s16].

The pivotal phase [iii]{.smallcaps} randomized controlled trial (750 patients) compared first-line sunitinib with [ifn]{.smallcaps}α and demonstrated a statistically significant advantage in objective response rate (39% vs. 8%, *p* \< 0.000001) and [pfs]{.smallcaps} (11 months vs. 5 months) with a hazard ratio ([hr]{.smallcaps}) of 0.42 (*p* \< 0.001) [@b12-co16-s1-s16]. The median [os]{.smallcaps} of the sunitinib and interferon groups was 26.4 months and 21.8 months respectively, which was of borderline statistical significance (*p* = 0.051), likely because patients who progressed on [ifn]{.smallcaps}α were allowed to cross over to receive [vegf]{.smallcaps}-targeted therapy [@b32-co16-s1-s16]. Notably, most of the enrolled patients (94%) had a favourable or intermediate risk by Memorial Sloan--Kettering Cancer Center ([mskcc]{.smallcaps}) prognostic criteria [@b39-co16-s1-s16]. Common toxicities included fatigue, hand--foot syndrome, diarrhea, mucositis, hypertension, and hypothyroidism. Cardiotoxicity has been reported, and thus monitoring may be required in patients with pre-existing heart disease [@b40-co16-s1-s16].

Because of these phase [ii]{.smallcaps} and [iii]{.smallcaps} trials, sunitinib has become a standard of care for the first-line treatment of metastatic [rcc]{.smallcaps}.

### 5.1.2. Sorafenib

Sorafenib was initially investigated for its ability to inhibit the Raf protein kinase, thereby affecting the mitogen-activated protein kinase signalling pathway responsible for downstream proliferation responses. However, it subsequently became clear that activity against [vegfr]{.smallcaps} 2, [vegfr]{.smallcaps} 3, [pdgf]{.smallcaps} beta, Flt-3, and c-Kit was also present [@b41-co16-s1-s16].

The Treatment Approaches in Renal Cancer Global Evaluation Trial, the largest study of previously-treated metastatic clear-cell [rcc]{.smallcaps}, enrolled 903 patients who were randomized either to oral sorafenib 400 mg twice daily or placebo [@b13-co16-s1-s16]. All patients enrolled had favourable or intermediate risk [mskcc]{.smallcaps} prognostic criteria. A clear median [pfs]{.smallcaps} benefit (5.5 months vs. 2.8 months) was observed in the sorafenib group. Objective response rate was minimal (10%, investigator-assessed), although more than 70% of patients had some degree of tumour burden reduction. The toxicities commonly experienced with sorafenib are similar to those experienced with sunitinib, except that the hand--foot syndrome may be more pronounced, and cardiotoxicity appears to occur less frequently.

Based on these data, sorafenib has been approved by the U.S. Food and Drug Administration ([fda]{.smallcaps}) and has become a standard of care for second-line treatment of metastatic [rcc]{.smallcaps} after immunotherapy failure. However, in a randomized phase [ii]{.smallcaps} trial of first-line sorafenib versus [ifn]{.smallcaps}α, a [pfs]{.smallcaps} benefit could not be demonstrated [@b42-co16-s1-s16]. Thus, sorafenib has assumed a largely second-line or later role in the treatment of metastatic [rcc]{.smallcaps}. The exception is the first-line use of sorafenib in patients unsuitable for sunitinib.

5.2. VEGF Ligand--Directed Therapy
----------------------------------

Bevacizumab is a recombinant monoclonal antibody that binds and neutralizes circulating [vegf]{.smallcaps}. The activity of this agent in [rcc]{.smallcaps} was initially identified by small randomized trials [@b43-co16-s1-s16],[@b44-co16-s1-s16]. A subsequent phase [iii]{.smallcaps} clinical trial randomized nephrectomized patients with clear-cell metastatic [rcc]{.smallcaps} to the combination of [ifn]{.smallcaps}α (three times weekly at a dose of 9×10[@b6-co16-s1-s16] IU for up to 1 year) plus bevacizumab \[10 mg/kg intravenously (IV) every 2 weeks\], or [ifn]{.smallcaps}α with placebo until disease progression [@b14-co16-s1-s16]. The addition of bevacizumab to [ifn]{.smallcaps}α significantly increased [pfs]{.smallcaps} (10.2 months vs. 5.4 months; [hr]{.smallcaps}: 0.63; *p* \< 0.0001) and the objective tumour response rate (31% vs. 13%, *p* \< 0.0001). A trend toward improved [os]{.smallcaps} was observed with the addition of bevacizumab, although results are not yet mature (*p* = 0.0670). A Cancer and Leukemia Group B phase [iii]{.smallcaps} trial of similar design confirmed a [pfs]{.smallcaps} (8.5 months vs. 5.2 months, *p* \< 0.0001) and an [orr]{.smallcaps} (25% vs. 13%, *p* \< 0.0001) benefit with bevacizumab plus [ifn]{.smallcaps}α 33. The final analysis of [os]{.smallcaps} is pending. Common toxicities included hypertension and proteinuria, with rare but serious toxicity including bowel perforation, arterial ischemic events, and bleeding.

Whether bevacizumab must be given in combination with interferon is unknown, because no bevacizumab monotherapy arm was used in the phase [iii]{.smallcaps} trials. Nevertheless, bevacizumab is important in the armamentarium of treatments for [rcc]{.smallcaps} and [fda]{.smallcaps} approval is pending.

5.3. mTOR Inhibitors
--------------------

Another downstream effect of the [vegfr]{.smallcaps} pathway is activation of Akt and phosphoinositide 3 kinase, which in turn promote m[tor]{.smallcaps} kinase. A component of intracellular pathways, m[tor]{.smallcaps} promotes tumour growth and proliferation, and is a mediator of the hypoxic response.

### 5.3.1. Temsirolimus

Temsirolimus is an [fda]{.smallcaps}-approved m[tor]{.smallcaps} inhibitor that binds to FK506 binding protein 1A to create a complex that directly inhibits m[tor]{.smallcaps}. A phase [iii]{.smallcaps} trial included 626 previously untreated patients with poor prognostic criteria and randomized them to temsirolimus 25 mg IV weekly, [ifn]{.smallcaps}α 18×10[@b6-co16-s1-s16] IU 3 times weekly, or temsirolimus plus [ifn]{.smallcaps}α 3 times weekly [@b16-co16-s1-s16]. Patients were required to have 3 or more of the following adverse risk features: Karnofsky performance status below 80Lactate dehydrogenase more than 1.5 times the upper limit of normalHemoglobin below the lower limit of normalSerum corrected calcium above 10 mg/dLLess than 1 year from first diagnosis of [rcc]{.smallcaps} to start of therapyThree or more metastatic sites

Of the patients included in this trial, 19% had non-clear-cell or unknown histology. Temsirolimus monotherapy demonstrated an [os]{.smallcaps} advantage in comparison with [inf]{.smallcaps}α (10.9 months vs. 7.3 months, log-rank *p* \< 0.008). The [orr]{.smallcaps} was 8.6% for temsirolimus and 4.8% for interferon, which was not a statistically significant difference. Common side effects included fatigue, hypercholesterolemia, and hyperglycemia. Temsirolimus has become a first-line standard of care for patients with metastatic [rcc]{.smallcaps}, appropriately applied to patients with poor prognostic criteria.

### 5.3.2. Everolimus

Another m[tor]{.smallcaps} inhibitor, everolimus (RAD001), has recently been reported in a phase [iii]{.smallcaps} trial to improve the [pfs]{.smallcaps} of patients with metastatic [rcc]{.smallcaps} who progressed on sunitinib, sorafenib, or both [@b45-co16-s1-s16]. These patients were randomized to daily oral everolimus 10 mg or placebo and were stratified by number of previous tyrosine kinase inhibitors ([tki]{.smallcaps}s) and [mskcc]{.smallcaps} "previously treated" risk groups (1 point each for anemia, hypercalcemia, and Karnofsky performance status below 80, with 0 points = favourable risk, 1 point = intermediate risk, and 2+ points = poor risk). The primary endpoint was [pfs]{.smallcaps}, and in the RAD001 and placebo groups, that endpoint was 4.0 months and 1.9 months respectively (*p* \< 0.0001). For the two groups, the [os]{.smallcaps} was not reached and 8.8 months respectively (*p* = 0.233, but the analysis is not yet mature). The benefit in [pfs]{.smallcaps} was seen in all three [mskcc]{.smallcaps} risk groups. Common side effects included asthenia, anemia, and stomatitis. This is the first second-line trial after initial [tki]{.smallcaps} failure to demonstrate benefit. Regulatory approval is pending.

6.. DRUGS IN DEVELOPMENT
========================

Axitinib (AG013736) is a small-molecule [tki]{.smallcaps} of [vegfr]{.smallcaps}, [pdgf]{.smallcaps} receptor, and c-Kit. A phase [ii]{.smallcaps} trial enrolled 62 treatment-refractory patients with [rcc]{.smallcaps} that had progressed on sorafenib [@b46-co16-s1-s16]. They were treated with oral axitinib 5 mg twice daily. Of 62 patients, 13 exhibited a partial response, and the median [pfs]{.smallcaps} was 7.4 months. An earlier phase [ii]{.smallcaps} trial enrolled cytokine-refractory nephrectomized patients who demonstrated a response rate of 44.2% and a median time to progression of 15.7 months with axitinib [@b47-co16-s1-s16]. Currently, a large multicentre phase [iii]{.smallcaps} trial is enrolling patients that progressed on sunitinib and is randomizing them to axitinib or sorafenib (search for "NCT00678392" at clinicaltrials.gov/ct2/search).

Pazopanib (GW786034) is another [tki]{.smallcaps} of [vegfr]{.smallcaps}s 1--3, [pdgf]{.smallcaps} receptors alpha and beta, and c-Kit. A randomized discontinuation study was initiated in patients who were treatment naïve (68%) or who had one line of immunotherapy (25%), bevacizumab (3%), or other non-targeted therapy (2%). The first 60 patients demonstrated good disease control rates, leading the Data and Safety Monitoring Committee to stop the discontinuation randomization phase and to allow all patients to continue the drug. Among the 225 patients with metastatic [rcc]{.smallcaps} enrolled, an [orr]{.smallcaps} of 27% was observed by independent review at 12 weeks [@b48-co16-s1-s16]. A first-line pazopanib versus sunitinib randomized controlled trial is currently recruiting (search for "NCT00720941" at clinicaltrials.gov/ct2/search).

Cediranib (AZD2171) is an potent inhibitor of [vegfr]{.smallcaps}s 1--3, [pdgf]{.smallcaps} receptor beta, and Flt-4. This oral agent has been studied by the Princess Margaret Hospital Consortium in a phase [ii]{.smallcaps} trial as first-line treatment in patients with progressive, unresectable, advanced metastatic [rcc]{.smallcaps} [@b49-co16-s1-s16]. Preliminary results indicate a partial response rate of 38% (6/16 patients). An additional 6 patients had stable disease, and 3 patients had progressive disease. Further trials examining this agent are warranted.

Volociximab is a chimeric monoclonal antibody against α5β1 integrin. The antibody blocks fibronectin in the extracellular matrix from binding to α5β1 integrin, inducing apoptosis of proliferating endothelial cells. Volociximab was studied in a multicentre phase [ii]{.smallcaps} study in patients with metastatic clear-cell [rcc]{.smallcaps} that enrolled 40 evaluable patients. It was well tolerated at 10 mg/kg given IV every 2 weeks. One subject achieved a partial response, and 32 subjects had stable disease [@b50-co16-s1-s16].

Inhibitors of c-Met such as XL880 and ARQ197 have been developed with the knowledge that genetic alterations in papillary [rcc]{.smallcaps} are different from those in clear-cell [rcc]{.smallcaps}. In patients with heritable disease, the c-met proto-oncogene on chromosome 7 is frequently duplicated [@b51-co16-s1-s16]. XL880 and ARQ197 are inhibitors of the c-Met [rtk]{.smallcaps}, which is mutated in most heritable papillary cancers and in some sporadic papillary cancers. Dose-finding phase [i]{.smallcaps} studies have been completed [@b52-co16-s1-s16],[@b53-co16-s1-s16], and these novel agents are currently being studied in patients with metastatic papillary [rcc]{.smallcaps} in phase [ii]{.smallcaps} trials (search for "NCT00345423" at clinical trials.gov/ct2/search). Preliminary results for XL880 (an inhibitor of c-Met and [vegfr]{.smallcaps} 2) have been reported in a phase [ii]{.smallcaps} trial that enrolled 20 evaluable patients: 3 of those patients had partial responses, and none had progressive disease [@b54-co16-s1-s16]. Of the patients enrolled in the phase [i]{.smallcaps} ARQ197 trial, 5 had advanced [rcc]{.smallcaps}. Of those 5 patients, 3 had stable disease, 1 had progressive disease, and 1 has yet to be reported [@b53-co16-s1-s16].

7.. FUTURE DIRECTIONS
=====================

Targeted therapies have now replaced the relatively ineffective complement of immunotherapeutic agents used in patients with metastatic [rcc]{.smallcaps}. Whether targeted therapies are best given in sequence or in combination, and what their role in the perioperative setting might be, is currently unclear.

A phase [ii]{.smallcaps} trial has completed enrolment of patients who progressed on sunitinib or bevacizumab and who are now receiving sorafenib based on the rationale that sorafenib may have non-cross-resistant activity in these patients. Of the 37 patients enrolled, 52% have experienced tumour shrinkage (defined as a 5% or greater decrease in tumour measurements), and 14% have experienced a true partial response by the Response Evaluation Criteria in Solid Tumors [@b55-co16-s1-s16]. These findings demonstrate that patients that have progressed on one [vegf]{.smallcaps} inhibitor can still respond to another [vegf]{.smallcaps} inhibitor. However, the effects of these second-line strategies on [pfs]{.smallcaps} or [os]{.smallcaps} are currently unclear and can be determined only in randomized trials, which are ongoing. At the present time, it remains unknown whether a patient who progressed on a [vegf]{.smallcaps} inhibitor should then be exposed to another [tki]{.smallcaps} or should be treated using an agent with a different mechanism of action (for example, the m[tor]{.smallcaps} inhibitor temsirolimus). A phase [iii]{.smallcaps} randomized trial in patients refractory to sunitinib is currently comparing temsirolimus with sorafenib (search for "NCT00474786" at clinicaltrials.gov/ct2/search).

Studies combining targeted therapies are being performed with the known caveat that combination therapies are associated with high financial cost and possibly increased toxicity because of overlapping side-effect profiles. A phase [i]{.smallcaps} trial of bevacizumab and sunitinib in a variety of solid tumours (led by the Cleveland Clinic) reported 1 unconfirmed partial response in a patient with papillary [rcc]{.smallcaps} from among 9 evaluable patients [@b56-co16-s1-s16]. Another phase [i]{.smallcaps} trial of this combination, given exclusively to patients with metastatic [rcc]{.smallcaps}, reported partial responses in 4 of 13 patients [@b57-co16-s1-s16]. A randomized phase [ii]{.smallcaps} trial studying the combination of bevacizumab and erlotinib \[an inhibitor of the epidermal growth factor receptor ([egfr]{.smallcaps}) pathway\] as compared with bevacizumab and placebo revealed no benefit for the active combination in terms of [orr]{.smallcaps} or [pfs]{.smallcaps} [@b44-co16-s1-s16]. Currently, combinations of targeted therapy remain experimental, and they should be administered only in the context of a clinical trial.

Targeted agents are also being studied in the adjuvant setting for patients with resected high-risk [rcc]{.smallcaps} and in the neoadjuvant setting in an attempt to downstage tumours before surgical resection of localized disease. The Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma Intergroup trial randomizes high-risk nephrectomized patients to one year of sorafenib, sunitinib, or placebo. Other trials such as the Sunitinib Trial in Advanced Renal Cancer (search for "NCT00326898" at clinicaltrials.gov/ct2/search) and the sorafenib versus placebo trial in patients with resected intermediate-or high-risk [rcc]{.smallcaps} (search for "NCT00492258" at clinicaltrials.gov/ct2/search) will help to elucidate the effect of these agents in the adjuvant setting. In the neoadjuvant setting, sunitinib in two preoperative cycles is being studied in a phase [ii]{.smallcaps} trial (search for "NCT00480935" at clinicaltrials.gov/ct2/search).

8.. CONCLUSIONS
===============

Targeted therapy has changed the landscape of treatment options for metastatic [rcc]{.smallcaps}. The disordered response to hypoxia found in [rcc]{.smallcaps} has been harnessed, making [vegf]{.smallcaps}, [pdgf]{.smallcaps}, and m[tor]{.smallcaps}-directed pathways a standard of care. This change has led to improved response rates and prolonged survival. New drug development, sequencing and combinations of drugs, and use of targeted drugs in the adjuvant and neoadjuvant settings are the subjects of ongoing clinical trials.

###### 

Selected clinical trials of targeted agents in metastatic renal cell carcinoma

  *Agent*                                             *Mechanism*                                                             *Population*                        *Trial arms*                                              *Efficacy* *[rr]{.smallcaps}* *(%)*   *[pfs]{.smallcaps}* *(months)*   *[os]{.smallcaps}* *(months)*
  --------------------------------------------------- ----------------------------------------------------------------------- ----------------------------------- --------------------------------------------------------- ------------------------------------- -------------------------------- -------------------------------
  Sunitinib [@b12-co16-s1-s16],[@b32-co16-s1-s16]     Tyrosine kinase inhibitor of [vegf]{.smallcaps} and related receptors   First line                          Sunitinib vs. interferon                                  39                                    11                               26.4
  8                                                   5                                                                       21.8                                                                                                                                                                 
  *p*\<0.000001                                       *p*\<0.001                                                              *p* =0.051                                                                                                                                                           
  Sorafenib [@b13-co16-s1-s16]                        Tyrosine kinase inhibitor of [vegf]{.smallcaps} and related receptors   Treatment-refractory, second line   Sorafenib vs. placebo                                     10                                    5.5                              17.8
  2                                                   2.8                                                                     15.2                                                                                                                                                                 
  *p*\<0.001                                          *p*\<0.01                                                               *p*=0.146                                                                                                                                                            
  Temsirolimus [@b16-co16-s1-s16]                     Inhibitor of m[tor]{.smallcaps}                                         Poor-risk first line                Temsirolimus vs. interferon                               8.6                                   [na]{.smallcaps}                 10.9
  4.8                                                 [na]{.smallcaps}                                                        7.3                                                                                                                                                                  
  [ns]{.smallcaps}                                                                                                            *p*\<0.008                                                                                                                                                           
  Bevacizumab [@b14-co16-s1-s16],[@b33-co16-s1-s16]   [vegf]{.smallcaps} ligand--binding antibody                             First line                          Bevacizumab plus interferon vs. placebo plus interferon   31, 25                                10.2, 8.5                        [na]{.smallcaps}
  13, 13                                              5.4, 5.2                                                                [na]{.smallcaps}                                                                                                                                                     
  *p*\<0.0001                                         *p*\<0.0001                                                                                                                                                                                                                                  

[rr]{.smallcaps} = risk ratio; [pfs]{.smallcaps} = progression-free survival; [os]{.smallcaps} = overall survival; [vegf]{.smallcaps} = vascular endothelial growth factor; m[tor]{.smallcaps} = mammalian target of rapamycin; [na]{.smallcaps} = not available; [ns]{.smallcaps} = nonsignificant.

###### 

Current treatment algorithm for patients with metastatic renal cell carcinoma

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Setting*                                        *Patients*                                               *Therapy (level 1 evidence)*                                             *Alternatives*
  ------------------------------------------------ -------------------------------------------------------- ------------------------------------------------------------------------ -------------------------------------------------------------------------
  First-line                                       Good or intermediate risk                                Sunitinib\                                                               High-dose interleukin-2\
                                                                                                            Bevacizumab[a](#tfn2-co16-s1-s16){ref-type="table-fn"} plus interferon   Sorafenib\
                                                                                                                                                                                     Observation\
                                                                                                                                                                                     Clinical trial

  Poor risk                                        Temsirolimus                                             Sunitinib\                                                               
                                                                                                            Clinical trial                                                           

  Second-line                                      Cytokine-refractory                                      Sorafenib                                                                Sunitinib\
                                                                                                                                                                                     Bevacizumab[a](#tfn2-co16-s1-s16){ref-type="table-fn"} plus interferon\
                                                                                                                                                                                     Clinical trial

  Prior [vegf]{.smallcaps} or m[tor]{.smallcaps}   Everolimus[a](#tfn2-co16-s1-s16){ref-type="table-fn"}\   Targeted therapy\                                                        
                                                   Clinical trial                                           not previously used\                                                     
                                                                                                            Clinical trial                                                           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Everolimus and bevacizumab are not yet approved by the U.S. Food and Drug Administration for metastatic renal cell carcinoma. [vegf]{.smallcaps} = vascular endothelial growth factor; m[tor]{.smallcaps} = mammalian target of rapamycin.
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